Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, ph...
Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, phase 3, MycarinG study
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundEstablish efficacy of rozanolixizumab (FcRn inhibitor) in generalised myasthenia gravis (gMG) across subgroups.Design/MethodsThe Phase 3 MycarinG study (MG0003/NCT03971422) randomised adults (MGFA Class II–IVa AChR/MuSK autoantibody-positive gMG) to weekly rozanolixizumab 7mg/kg, 10mg/kg or placebo for 6 weeks. The primary endpoint was le...
Alternative Titles
Full title
Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, phase 3, MycarinG study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2894695999
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2894695999
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/JNNP-2023-ABN.253
